Program
Epigenetic Abnormalities and Therapies for Hematologic Malignancies
Tentative Program
Friday, 27 July, 2018 | ||
8:50-9:00 | Opening Remarks | |
9:00-10:00 | Asian Session 1 : Hematological Leaders of Asia | |
Chair | Dr. Hitoshi Kiyoi (Nagoya University Graduate School of Medicine) | |
Dr. Takahiro Maeda (Kyushu University Hospital) | ||
Speaker | Dr. Ai Kotani (Tokai University, School of Medicine) Potent Microenvironment Changer: EBV Derived Exosome |
|
Dr. Wen-Chien Chou (National Taiwan University Hospital, Chinese Taipei) The Clinical and Biological Features of HOPX in de Novo Acute Myeloid Leukemia |
||
Dr. Tao Cheng (Chinese Academy of Medical Sciences & Peking Union Medical College, China) Incompetence of Normal Hematopoiesis in Leukemia and Its Mechanisms |
||
Asian Session 2 : Hematological Leaders of Asia | ||
Chair | Dr. Issay Kitabayashi (National Cancer Center Research Institute) | |
Dr. Yoshinobu Kanda (Jichi Medical University) | ||
Speaker | Dr. Hao Jiang (People’s Hospital, Peking University, China) Efficacy and Safety of Decitabine in Combination with G-CSF, Low-dose Cytarabine and Aclarubicin in MDS-EB and AML-MRC |
|
Dr. Akihiko Yokoyama (National Cancer Center) Transcriptional Mechanism that Drives MLL-Rearranged Leukemia |
||
Dr. Yoo-Jin Kim (Seoul St.Mary’s Hospital, The Catholic University of Korea, Korea) Hypomethylating Therapy in Stem Cell Transplantation for MDS |
||
10:00-10:10 | Break | |
10:10-11:50 | Plenary Session 1 : Epigenetic Abnormalities of Hematological Malignancies; Basic Studies | |
Chair | Dr. Takanori Teshima (Hokkaido University) | |
Dr. Hideo Harigae (Tohoku University Graduate School of Medicine) | ||
Speaker | Dr. Hiroaki Honda (Tokyo Women's Medical University) Roles of Two Demethylases for Histone H3K27, JMJD3 and UTX, In Normal Hematopoiesis and Leukemogenesis |
|
Dr. Daniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA) Oncogenic Innate Immune Signaling in MDS and AML |
||
Dr. Mineo Kurokawa (The University of Tokyo) Modeling ASXL1 Mutation Revealed Impaired Hematopoiesis Caused by Derepression of p16Ink4a through Aberrant PRC1-mediated Histone Modification |
||
Dr. Maria E. Figueroa (University of Miami Miller School of Medicine, USA) Epigenetic Deregulation in Aging and MDS |
||
11:50-12:05 | Break | |
12:05-12:50 | Luncheon Seminar 1 (Co-Sponsored by Chugai Pharmaceutical Co., Ltd.) | |
Chair | Dr. Kenichi Ishizawa (Yamagata University) | |
Speaker | Dr. Ari Melnick (Weill Cornell Medicine, USA) Biology of Follicular Lymphoma |
|
12:05-12:50 | Luncheon Seminar 2 (Co-Sponsored by Celegine K.K.) | |
Chair | Dr. Shinsuke Iida (Nagoya City University Graduate School of Medical Sciences) | |
Speaker | Dr. Irene M. Ghobrial (Harvard Medical School : Steven and Michelle Kirsch Laboratory : Dana-Farber Cancer Institute, USA) Multiple Myeloma: Disease Mechanism and Treatment Strategy |
|
12:50-13:55 | Poster Viewing | |
13:55-15:35 | JSH-EHA Joint Session : Epigenetics of Myeloproliferative Neoplasm (MPN) | |
Chair | Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine) | |
Dr. Shinji Nakao (Kanazawa University) | ||
Speaker | Dr. Atsushi Iwama (Chiba University) Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms |
|
Dr. Kazuya Shimoda (University of Miyazaki) The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis |
||
Dr. Radek C. Skoda (University Hospital Basel, Switzerland) Molecular Pathogenesis of Myeloproliferative Neoplasms |
||
Dr. Tony Green (University of Cambridge, UK) Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions |
||
15:35-15:55 | Break | |
15:55-17:35 | Plenary Session 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies | |
Chair | Dr. Yoshinobu Maeda (Okayama University Hospital) | |
Dr. Yasushi Miyazaki (Nagasaki University) | ||
Speaker | Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine) Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity |
|
Dr. Brian Huntly (University of Cambridge, UK) Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation |
||
Dr. Shigeru Chiba (University of Tsukuba) TET2 Dioxygenase Activity in AML Development |
||
Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA) NAD+ Metabolism, TET2 Activity and Other Aspects of Hematopoietic Stem Cell Aging |
||
17:35-17:45 | Break | |
17:45-18:15 | Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis | |
Chair | Dr. Atsushi Hirao (Kanazawa University) | |
Dr. Yoshio Katayama (Kobe University Hospital) | ||
Speaker | Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo) A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis |
|
Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine) Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia |
||
Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences) Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs |
||
Welcome Reception |
Saturday, 28 July, 2018 | ||
8:00-8:45 | Morning Seminar 1 (Co-Sponsored by Eisai Co., Ltd. ) | |
Chair | Dr. Akifumi Takaori-Kondo (Kyoto University) | |
Speaker | Dr. Jonathan D. Licht (University of Florida Health Cancer Centerm, USA) Epigenetic Deregulation in Blood And Other Malignancies -Focus on EZH2- |
|
8:00-8:45 | Morning Seminar 2 (Co-Sponsored by SymBio Pharmaceuticals Limited. /Onconova Therapeutics, Inc.) | |
Chair | Dr. Hideki Muramatsu (Nagoya University Graduate School of Medicine) | |
Speaker | Dr. Lewis R Silverman (The Mount Sinai Hospital and School of Medicine, USA) Rigosertib-Strategies in MDS and Pediatric Rasopathies |
|
8:45-8:50 | Break | |
8:50-10:10 | Plenary Session 3 : Clinical Studies and New Epigenetic Therapies for Hematological Malignancies | |
Chair | Dr. Itaru Matsumura (Kindai University) | |
Dr. Norio Komatsu (Juntendo University) | ||
Speaker | Dr. Ravi Majeti (Stanford University, USA) Epigenetic Dysregulation in Human AML Stem Cells |
|
Dr. Issay Kitabayashi (National Cancer Center Research Institute) Cancer Stem Cell-Targeted Therapy for Hematological Malignancy Based on Dual Inhibition of EZH1/EZH2 |
||
Dr. Jonathan D. Licht (University of Florida Health Cancer Center, USA) Deregulation and Oncogenic Functions of the NSD2/MMSET Histone Methyl Transferase in Hematological Malignancies |
||
10:10-10:20 | Break | |
10:20-12:00 | JSH-ASH Joint Session : Epigenetics of Hematological Malignancies | |
Chair | Dr. Koichi Akashi (Kyushu University) | |
Dr. Hideaki Nakajima (Yokohama City University Graduate School of Medicine) | ||
Speaker | Dr. Omar Abdel-Wahab (Memorial Sloan Kettering Cancer Center, USA) Coordinated Alterations in RNA Splicing and Epigenetic Regulation Drive Leukemogenesis |
|
Dr. Toshio Kitamura (The Institute of Medical Science, University of Tokyo) EZH2 Mutations Induce MDS-like Symptoms in Mouse BMT Models via Overexpression of ABC-G2 and Inhibition of Bone Formation |
||
Dr. Seishi Ogawa (Kyoto University) Stag2 Regulates Hematopoietic Differentiation and Self-Renewal |
||
Dr. Margaret Goodell (Baylor College of Medicine, USA) DNA Methyltransferase 3A in Normal and Malignant Hematopoiesis |
||
12:00-12:15 | Break | |
12:15-13:00 | Luncheon Seminar 3 (Co-Sponsored by Nippon Shinyaku Co.,Ltd.) | |
Chair | Dr. Hideaki Nakajima (Yokohama City University Graduate School of Medicine) | |
Speaker | Dr. Daniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA) Novel Therapeutic Targets in Myeloid Malignancies |
|
Luncheon Seminar 4 (Co-Sponsored by Bristol-Myers Squibb K.K.) | ||
Chair | Dr. Koichi Akashi (Kyushu University) | |
Speaker | Dr. Brian Huntly (University of Cambridge, UK) Leukaemia Stem Cells : Root of Persistence and Transformation and True Therapeutic Target in CML |
|
13:00-13:10 | Break | |
13:10-14:10 | Sweets Seminar Special Lecture 1・2 : Epigenetic Aspects of Hematological Malignancies and Their Therapies | |
Chair | Dr. Yuzuru Kanakura (Osaka University Graduate School of Medicine) | |
Dr. Masahiro Kizaki (Saitama Medical Center, Saitama Medical University) | ||
Speaker | Dr. Raphael Itzykson (Hopital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris Diderot University, France) Recent Insight on the Clinical Use of Hypomethylating Agents |
|
Dr. Ari Melnick (Weill Cornell Medicine, USA) Epigenetic Basis of Germinal Center Derived B-cell Lymphomas |
||
14:10-14:15 | Closing Remarks |